Ashlins Pharmaceuticals selects drug candidates with existing pre‑clinical or clinical evidence to accelerate regulatory approval for rare, underserved diseases, focusing on vision‑threatening ocular conditions. By evaluating regulatory feasibility, manufacturing scalability, and market sustainability, it advances therapies like its lead biologic AIS‑001 toward registration, shortening treatment timelines for patients and clinicians.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with severe rare and underserved diseases often lack approved therapies, leading to delayed treatment, off‑label use, and prolonged suffering. In rare ocular conditions that threaten vision, the absence of dedicated drug development further limits timely access to effective care.
Solution
Ashlins Pharmaceuticals identifies therapeutic candidates that already have scientific or clinical evidence supporting their use, enabling a more efficient regulatory pathway. By evaluating each program for clinical need, regulatory feasibility, manufacturability, and commercial sustainability, the company accelerates development toward approval. Its lead program, AIS‑001, is a biologic targeting an adult, vision‑threatening rare ocular disease and is currently in registrational planning. Ashlins focuses its resources on advancing such evidence‑backed therapies to market, aiming to shorten the wait for patients who have few or no treatment options.
Target Audience
Primary customers are rare‑disease patients and their ophthalmologists, as well as healthcare systems and payers seeking approved treatments for underserved ocular conditions.
Features
- Systematic selection of drug candidates with existing pre‑clinical or clinical data to reduce development timelines
- Comprehensive feasibility assessment covering regulatory strategy, manufacturing scalability, intellectual property, and market sustainability
- Dedicated rare‑disease focus that prioritizes patient need over market size
- Development of AIS‑001, a biologic therapy progressing through IND, Phase 1‑3 toward registration for a vision‑threatening ocular indication
- Commitment to transparent, patient‑centric communication and rapid progression to market access